Moderna Stock Is Top S&P Performer After Miserable 2023. Why This Year Could Be Better.
1 min read
Moderna stock was one of the worst performers in the S&P 500 last year as Covid-19 vaccine sales tumbled, but the vaccine maker has more to offer, according to Oppenheimer analysts.
Continue reading this article with a Barron’s subscription.
View Options
2024-01-02 10:18:00
All news and articles are copyrighted to the respective authors and/or News Broadcasters. VIXC.Com is an independent Online News Aggregator
Read more from original source here…
